Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

The purpose of this study is to learn more about how a new study agent works inside the body. This study agent is a protein called 68Ga-F(ab')2-trastuzumab fragments (HERScan). This is a radioactive tracer that was developed at MSKCC to target the HER2 protein on cancer cells. By giving this tracer to patients whose cancers have the HER2 protein, we hope to be able to see the level of HER2 on the cancer cells using PET scanning.

Key facts

Study ID

NCT00613847

Run by

Memorial Sloan Kettering Cancer Center

People needed

17

Starts

2006-10-01

Expected to finish

2013-12-01

Last updated by the study team

2020-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Registered patient at MSKCC
• Age ≥ or = to 18 years
• Patients with invasive solid tumors.
• Measurable or evaluable disease
• Patients must have had routine disease staging studies with CT scan, FDG PET/CT scan, bone scan and/or MRI within 8 weeks of enrollment onto this trial
• Karnofsky Performance Score ≥ or = to 60
• Signed informed consent

You may not qualify if…

• Claustrophobia/pain or any other disability leading to inability to lie still for the duration of the scanning procedure.
• Pregnancy Test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material.
• Patients with known sensitivity or contraindication to Herceptin.
• Inability to provide written informed consent.

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.